Compare Abeona Therapeutics Inc (ABEO) vs Chevron Corp (CVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Chevron Corp — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Chevron Corp trades at $197.15 (market cap $385.77B). The key difference: Chevron Corp is far larger — about 915.9× Abeona Therapeutics Inc's market cap, and Chevron Corp pays a 3.62% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CVX | |
|---|---|---|
Market Cap | $421.19M | $385.77B |
Sector | Health | Energy |
52-Week High | $7.45 | $211.14 |
52-Week Low | $4.17 | $146.72 |
Enterprise Value | $276.10M | $414.31B |
Volume | — | 9,807,834 |
Dividend Yield | — | 3.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
CVX trades at $194.9, up 4.47% today, with a bullish technical signal and strong analyst support. Recent earnings consistently beat expectations, with Q2 2026 EPS of $6.06 exceeding the $5.55 forecast. The company maintains solid profitability with a 9.87% net margin and 12.25% ROE, supported by a $13.8 billion investment in Argentina's Vaca Muerta shale project announced on June 2, 2026 (Reuters).
Outlook remains positive with a consensus price target of $214.25, implying 10% upside. Risks include declining revenue from $184.43B in 2025 and exposure to volatile oil prices, but high oil prices and strategic expansions provide growth catalysts. The stock offers a steady dividend of $1.78 per half-year.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →
